Paclitaxel for treatment of advanced small cell lung cancer (SCLC)

• Verfasst von: Eiff, Damian von [VerfasserIn]
• Verfasst von: Bozorgmehr, Farastuk [VerfasserIn]
• Verfasst von: Chung, Inn [VerfasserIn]
• Verfasst von: Bernhardt, Denise [VerfasserIn]
• Verfasst von: Rieken, Stefan [VerfasserIn]
• Verfasst von: Liersch, Stephan [VerfasserIn]
• Verfasst von: Muley, Thomas [VerfasserIn]
• Verfasst von: Kobinger, Sonja [VerfasserIn]
• Verfasst von: Thomas, Michael [VerfasserIn]
• Verfasst von: Christopoulos, Petros [VerfasserIn]
• Verfasst von: Steins, Martin [VerfasserIn]
• Titel: Paclitaxel for treatment of advanced small cell lung cancer (SCLC)
• Titelzusatz: a retrospective study of 185 patients
• Verf.angabe: Damian von Eiff, Farastuk Bozorgmehr, Inn Chung, Denise Bernhardt, Stefan Rieken, Stephan Liersch, Thomas Muley, Sonja Kobinger, Michael Thomas, Petros Christopoulos, Martin Steins
• E-Jahr: 2020
• Jahr: [2020]
• Umfang: 12 S.
• Fussnoten: Gesehen am 17.04.2020
• Titel Quelle: Enthalten in: Journal of thoracic disease
• Ort Quelle: Hong Kong : Pioneer Bioscience Publ., 2009
• Jahr Quelle: 2020
• Band/Heft Quelle: 12(2020), 3, Seite 782-793
• ISSN Quelle: 2077-6624
• DOI: doi:10.21037/jtd.2019.12.74
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1694876837
• K10plus-PPN:
  Universitätsbibliothek
• Lokale URL UB: Zum Volltext

Abstract

Background: Etoposide-/platinum-based chemotherapy is the standard first-line treatment for extensive- disease small cell lung cancer (SCLC), but responses are short-lived and subsequent options limited. Here, we present our experience with paclitaxel in advanced treatment lines. - Methods: We retrospectively studied the clinical course of all paclitaxel-treated SCLC patients between 2005 and 2015 in our institution. Prognostic and predictive factors were analyzed by Kaplan-Meier and Cox regression analyses. - Results: A total of 185 patients [119 men, median age 65 years, median ECOG performance status (PS) 1] were identified. One hundred and sixty-eight patients had extensive disease (ED) at the time of paclitaxel therapy. Paclitaxel was mainly given as third- or fourth-line therapy (93%). The response rate (RR) was 17% and disease control rate (DCR) 28%. Patients reached a median progression-free survival (PFS) of 1.6 (95% CI: 1.4-1.8) months and median overall survival (OS) of 3.3 (95% CI: 2.8-3.9) months. Main toxicities were fatigue (25%) and polyneuropathy (17%). Dose reduction of ≥25% was associated with shorter PFS [1.9 (95% CI: 1.5-2.3) vs . 1.4 (95% CI: 1.3-1.5) months; P=0.004]. Further independent predictive factors for PFS were gender, age, and hepatic/brain metastases (P vs . 62%), as well as a comparable DCR (29% vs . 28%), which was associated with prolonged survival (4.5 vs . 3.2 months for refractory cases, P=0.034). - Conclusions: Paclitaxel has clinically relevant activity in heavily pretreated SCLC. While patients with good PS and no cerebral/hepatic metastases derive the greatest benefit, ECOG PS 2 per se should not be used as a criterion to exclude patients.